COMPASS THERAPEUTICS, INC. Financials Compass Therapeutics, Inc. OTC Markets
Equities
CMPX
US20454B1044
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.55 USD | -10.80% |
|
+32.67% | -.--% |
| 05-13 | Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-06 | Top Premarket Gainers | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 309 | 633.5 | 198.8 | 220.1 | - | - |
| Enterprise Value (EV) 1 | 309 | 633.5 | 198.8 | 220.1 | 220.1 | 220.1 |
| P/E ratio | -2.42 x | -13.6 x | -4.73 x | -4.17 x | -3.67 x | -8.68 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 21.6 x | 2.52 x |
| EV / Revenue | - | - | - | - | 21.6 x | 2.52 x |
| EV / EBITDA | -3.8 x | -15.5 x | -4 x | -3.79 x | -3.46 x | -3.55 x |
| EV / FCF | -14,336,714 x | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 97,472 | 125,938 | 127,455 | 137,589 | - | - |
| Reference price 2 | 3.170 | 5.030 | 1.560 | 1.600 | 1.600 | 1.600 |
| Announcement Date | 18/03/22 | 15/03/23 | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 10.17 | 87.2 |
| EBITDA 1 | - | -81.32 | -40.87 | -49.66 | -58.16 | -63.62 | -61.96 |
| EBIT 1 | - | -81.88 | -41.66 | -50.36 | -57.57 | -71.5 | -38.35 |
| Operating Margin | - | - | - | - | - | -702.99% | -43.98% |
| Earnings before Tax (EBT) 1 | -29.47 | -82.18 | -39.22 | -42.49 | -53.16 | -69.07 | -35.18 |
| Net income 1 | -29.5 | -82.18 | -39.22 | -42.49 | -53.16 | -71.23 | -31.72 |
| Net margin | - | - | - | - | - | -700.29% | -36.38% |
| EPS 2 | - | -1.310 | -0.3700 | -0.3300 | -0.3840 | -0.4357 | -0.1843 |
| Free Cash Flow | - | -21.55 | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 05/03/21 | 18/03/22 | 15/03/23 | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -12.88 | -7.017 | -8.767 | -12.4 | -12.69 | -9.517 | -13.16 | -11.76 | -15.23 | -12.62 | -13.98 | -15.06 | -16.4 | -14.67 | -14.95 |
| EBIT 1 | -13 | -7.182 | -8.987 | -12.6 | -12.89 | -9.711 | -13.34 | -11.93 | -15.39 | -12.77 | -13.82 | -13.95 | -15.42 | -14.82 | -15.11 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -12.99 | -7.162 | -8.494 | -11.98 | -11.59 | -7.837 | -11.28 | -9.964 | -13.42 | -10.79 | -12.93 | -13.47 | -15.26 | -14.82 | -15.11 |
| Net income 1 | -12.98 | -7.162 | -8.494 | -11.98 | -11.59 | -7.837 | -11.28 | -9.964 | -13.42 | -10.79 | -12.93 | -13.47 | -15.26 | -14.82 | -15.11 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.0500 | -0.0700 | -0.0800 | -0.1200 | -0.1000 | -0.0600 | -0.0900 | -0.0800 | -0.1100 | -0.0800 | -0.0940 | -0.0980 | -0.1060 | -0.0900 | -0.0900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 18/03/22 | 09/05/22 | 01/08/22 | 09/11/22 | 15/03/23 | 04/05/23 | 03/08/23 | 09/11/23 | 21/03/24 | 13/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -21.6 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 1.89 | 0.21 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 05/03/21 | 18/03/22 | 15/03/23 | 21/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.6
USD
Average target price
9
USD
Spread / Average Target
+462.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- CMPX Stock
- CMPX Stock
- Financials Compass Therapeutics, Inc.
